Versartis - Improving Therapies, Improving Lives

 

About Versartis   Upcoming Events  

Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. 

Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. 

Partner with Versartis
The company is interested in exploring partnerships on our products to accelerate the development process and ensure successful commercialization. 

 

 

Apr 30 2013Journal of Clinical Endocrinology & Metabolism Publishes Positive Versartis Phase I Data

Jan 15 2013
Versartis Closes $25 Million Series C Financing Oct 24 2012
Versartis Initiates VERTICAL Trial of Long Acting Human Growth Hormone in Children with Growth Hormone Deficiency

 

Versartis Trial in Children to Assess Long-Acting Growth Hormone (VERTICAL)